Research on Fabry disease highlights the importance of early treatment with agalsidase alfa to improve patient outcomes. This enzyme replacement therapy is shown to slow the progression of renal and cardiac complications, leading to better quality of life and potentially longer life expectancy.
By comparing treated patients with untreated cohorts, studies demonstrate that timely intervention can prevent severe health issues. Effective treatment reduces disease severity and mortality rates, emphasizing the need for ongoing monitoring and intervention in Fabry disease management (Ramaswami et al., 2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
